Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Artificial Solutions: Invitation to presentation of Q1 report 2020 and Postpones Publication of Annual Report

Artificial Solutions® (FNSE:ASAI ), the leading specialist in enterprise-strength conversational AI, will release the interim report for the first quarter of 2020 on Monday 18[th] May 2020 at 07:30 am (CET).The full report and a brief presentation will be available on www.artificial-solutions.com/investor-relations.   Conference call details Lawrence Flynn, CEO and Chris Bushnell, CFO will present the financial results at a telephone conference at 10:00 CET the same day. In order to participate in the conference call, please

Lifco acquires a product portfolio from TrollDental

Lifco  has signed an agreement to acquire a product portfolio from the Swedish company TrollDental . The company is a niche manufacturer of dental products. In 2019, the acquired product portfolio reported net sales of approximately 25 MSEK. The most prominent brands in the product portfolio are TrollFoil, TrollBag and TrollByte. The business will be consolidated in Business Area Dental. The acquisition will not have any significant effect on Lifco’s earnings or financial position in current financial year. Please visit www.trolldental.

FluoGuide A/S is awarded Best IPO in 2019 by the independent IPO Guide

Copenhagen, Denmark, 15 May 2020 – Affärsvärlden’s IPO Guide announced that FluoGuide A/S (“FluoGuide”) won the 2019 share price development award in the micro-cap category and also received the honorary quality award. The IPO Guide is an independent analysis group that has reviewed all Swedish IPOs since 2017.FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces

Report from Ambea´s Annual shareholders’ meeting 15 May 2020

Stockholm – Ambea AB (publ) (“Ambea”) today reports that the company's annual shareholders meeting’ held today voted to support all of the resolutions that the board of directors and nomination committee proposed to the annual shareholders’ meeting.The annual shareholders’ meeting re-elected Lena Hofsberger, Daniel Björklund, Anders Borg, Gunilla Rudebjer, Lars Gatenbeck, Mikael Stöhr and Liselott Kilaas as members of the board of directors. Lena Hofsberger was re-elected as chairman of the board of directors. The annual shareholders’ meeting re-elected Ernst & Young AB as auditor until

Oncopeptides presents pre-clinical melflufen data at the AACR Annual Meeting 2020 that further validates the technical platform, PDC

STOCKHOLM — May 15, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen (melphalan flufenamide) have been selected for presentation at the American Association for Cancer Research (AACR). The poster presentations are now available online.Melflufen is a first-in-class anticancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in late stage clinical development as a potential treatment of patients with relapsed refractory multiple myeloma (RRMM).

Summary from the annual general meeting 2020 of Raketech Group Holding Plc.

The shareholders of Raketech gathered in Stockholm, Sweden, on 15 May 2020 to hold an annual general meeting. The following resolutions were made.It was resolved to approve the Consolidated Financial Statements of the company, the Director’s Report and the Auditor’s Report for the financial year ending 31 December 2019. The meeting resolved to not pay any dividends for the financial year 2019 in accordance with the directors’ recommendation as set forth in the Directors’ Report. Christian Lundberg, Annika Billberg, Fredrik Svederman, Erik Skarp and Johan Svensson were re-elected as

Announcement from the Annual General Meeting of Talkpool AG Friday, May 15, 2020

The Chairman of the Board of Directors, Magnus Sparrholm opened the Annual General Meeting of Talkpool AG. He introduced the consolidated financial statements highlighting net revenues for 2019 of EUR 21.233 million and a net loss of EUR 3.376 million. The Annual General Meeting resolved the annual report to carry forward a loss of CHF 3’141’856 for the parent company Talkpool AG in 2019. After appropriation of the annual loss, the total loss carry forward amounts to CHF 5’483’166 in the parent company. All Board members and the President were discharged from liability for the past

Flexibility key to enabling shipping’s transition to future fuels

Wärtsilä Corporation, News, 15 May 2020 at 11:30 AM E. Europe Standard TimeWärtsilä is developing an unprecedented range of engine and fuel gas supply systems to help ship owners navigate the route to reduced greenhouse gas emissions – whichever fuels they choose. As shipping seeks to drastically cut emissions, which fuels it will use to do so are far from clear. For 100 years the marine fuel market has been dominated almost entirely by oil. Now a diverse palette of potential clean fuel is emerging. The viability of many new fuels depends on overcoming many challenges over the next 10

Orexo´s partner Gesynta Pharma announces positive results from phase 1 study for OX-MPI

Uppsala, Sweden – May 15, 2020 – Orexo´s partner, Gesynta Pharma,  today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory conditions. The purpose of the first clinical study was to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI (GS-248) after single and multiple ascending doses to healthy subjects. The results support further clinical development of OX-MPI (GS-248) and a clinical phase II study is

Health and safety is the number one challenge to getting SMEs back to work

A LEADING legal firm is urging business owners to make sure they are up to date on legislation after a poll revealed health and safety as the number one challenge to getting staff back to work as lockdown eases.   With thousands of people set to head back to work as restrictions are gradually lifted, company bosses and individual workers are being advised to make sure they fully understand their legal obligations - and the consequences of failing to comply.  A poll of SMEs across the UK conducted by the UK200Group, an organisation which represents the country’s leading law and

New Board of directors elected at the AGM in FundedByMe. All decisions were taken unanimously*

Yesterday, Thursday, May 14th, 2020, FundedByMe Crowdfunding Sweden AB (publ) held an Annual General Meeting. At the AGM, the shareholders resolved, among other things, the following:The Meeting resolved To establish the income statement and balance sheet for the fiscal year 2019. To dispose of the Company's loss in accordance with the Board's proposal; and To grant discharge to the members of the Board of Directors and the CEO. The Annual General Meeting resolved to stipulate that fees shall be paid in accordance with previous years' remuneration and remain at a remuneration of

First patient enrolled in SESAR study on lung protection

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that that the first patient has been included in SESAR, the world's largest multicenter study with AnaConDa to evaluate whether inhaled sedation via AnaConDa has lung-protective properties, promotes shortened ventilator time and higher survival in intensive care patients with acute respiratory failure. An addendum to the study has recently been made to study covid-19 patients in a separate sub-study.As previously announced, Sedana Medical provides financial support to SESAR, a prospective, randomized and controlled study

Etteplan Oyj - Managers' Transactions

Etteplan Oyj, Stock Exchange Release, May 15, 2020, at 11.00 a.m.   ETTEPLAN OYJ - Managers' Transactions____________________________________________ Person subject to the notification requirementName: INGMAN ROBERTPosition: Member of the Board/Deputy member(X) Legal personIssuer: ETTEPLAN OYJLEI: 7437006I5533R06JU690 Notification type: INITIAL NOTIFICATIONReference number: 7437006I5533R06JU690_20200514195749_2____________________________________________ Transaction date: 2020-05-14Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009008650

Resolutions at the annual general meeting in Scandi Standard AB (publ)

At the annual general meeting in Scandi Standard today on 15 May 2020, it was resolved on, among other things, re-election of all board members and election of Henrik Hjalmarsson as a new board member, re-election of the auditor, implementation of a long-term incentive program (LTIP 2020) and an authorisation for the board to resolve on issues of shares. Adoption of income statements and balance sheetsThe annual general meeting adopted the income statement and the balance sheet as well as the consolidate income statement and the consolidate balance sheet for the financial year 2019.

Scandion Oncology’s drug SOM-001 demonstrates antibiotic activity in a mouse model infected with MRSA bacteria

Scandion Oncology has received positive results on the antibiotic in vivo effects of SOM-001 and has decided to proceed with preclinical testing.Antibiotic bacterial resistance is a serious medical problem with a high morbidity and mortality of the infected patients. Previously, Scandion Oncology announced that one of its compounds, SOM-001 and a number of analogues have strong anti-bacterial effects also in otherwise antibiotic resistant bacteria. Moreover, SOM-001 kills bacteria via a novel mechanism of action and further, resistance to SOM-001 has not been observed during in vitro

NetEnt Live unveils new-look lobby to boost player engagement

Supplier puts players front and centre of fresh design with intuitive user interface NetEnt has further enhanced its Live Casino offering with a player-orientated Lobby and Mini-Lobby that enables seamless navigation between games.  The modern, user-friendly design displays the latest information on the tables, including winning numbers, available seats, bet limits and the number of players. Dynamic table tiles with live images of the game presenter and background create a truly immersive experience, and players are presented with a more intuitive table ordering to cross

Multiconsult: Change in reporting segment structure 2020

Multiconsult has made changes to the Group's segment reporting,Multiconsult’s reporting segments has historically been presented as four segments. As from 2020 Multiconsult’s reporting segments will be five segments: Region Oslo, Region Norway, Energy, LINK arkitektur and International. Region Oslo: This segment offers services in seven business areas and comprises the Oslo region, in addition the segment includes Multiconsult’s internal segment Large Projects in Norway. Region Norway: This segment offers services in seven business areas and comprises all offices outside Oslo with

The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue

NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approval by an extraordinary general meeting in the Company. The Company’s largest shareholder Diamyd Medical AB and chairman of the Boad of Directors Anders Essen-Möller have undertaken to subscribe for their pro rata share in the Rights Issue. In total, the Rights Issue is covered by subscription

Nokian Tyres is the first tire company to have its ambitious greenhouse gas reduction targets approved

Nokian Tyres plc Company Release May 15, 2020 at 10:00 a.m. Nokian Tyres is the first tire company to have its emissions reduction targets approved by the Science Based Targets initiative (SBTi). The targets covering greenhouse gas (GHG) emissions from Nokian Tyres’ operations (scopes 1 and 2*) are consistent with reductions required to keep climate warming to 1.5°C, what the latest climate science has told us is needed to prevent the most damaging effects of climate change. Nokian Tyres plc commits to reduce GHG emissions by 2030 in the following categories: · scope 1 and 2 GHG

Ahlstrom-Munksjö, Filterpak and K Group to start the production of face masks in Finland

AHLSTROM-MUNKSJÖ OYJ PRESS RELEASE MAY 15, 2020 at 10.00 EEST Ahlstrom-Munksjö, Filterpak and K Group will start in co-operation the production and supply of face masks for civil use in Finland. The first batch of masks will be available at the end of May. In the co-operation, Ahlstrom-Munksjö is responsible for the production of the fiber-based mask materials at its plant in Tampere and Filterpak for the assembly of the masks in Hanko. Finland-based retailer K Group has ordered the masks and will take care of their logistics and supply. The filtration efficiency of the masks is 88%

NoHo Partners begins co-operation negotiations on continuing temporary layoffs due to uncertain market situation

NoHo Partners PlcINSIDE INFORMATION 15 MAY 2020 at 10:00NoHo Partners begins co-operation negotiations on continuing temporary layoffs due to uncertain market situation On 13 March 2020, NoHo Partners announced it would start temporary layoffs, of 90 days at most, in order to minimise the negative financial impact of the coronavirus (COVID-19) on its business. The current temporary layoffs concern nearly all of the Group’s employees, which comprises about 1,300 people. The layoffs are estimated to continue until the end of June 2020.Due to the uncertain market situation NoHo

2020 Bulkers Ltd. (2020) – Time charter agreements for Bulk Sao Paulo and Bulk Santos

Hamilton, Bermuda, May 15, 2020 2020 Bulkers has entered into time charter agreements for Bulk Sao Paulo and Bulk Santos with a 100% owned subsidiary of Glencore. The vessels will commence their respective 35-37 month time charters upon delivery from New Times Shipyard in early June 2020, and will earn an index-linked rate, reflecting a significant premium to the Baltic 5TC index. The time charters also include a profit sharing of any economic benefit derived from operating the vessels scrubbers, as well as certain rights to convert the time charters to fixed rates on the basis of the

BioStock: Immunicum’s immuno-oncology platform shares the spotlight at Cancer Progress conference

The field of immuno-oncology encompasses several strategies to push our own immune system to be more sensitive and reactive to cancer cells and metastases. Swedish biotech Immunicum have developed their own strategy and were asked to present and discuss it on a panel of immuno-oncology experts at the 31st Annual Cancer Progress Conference last week. BioStock caught up with Immunicum’s COO, Sijme Zeilemaker, who represented the company on that panel, to learn more about the discussion and how Immunicum is making a difference in the field.Read the full interview with Sijme Zeilemaker at

Interim Report 1 January to 31 March 2020

Summary of the interim reportFirst Quarter (1 January to 31 March 2020) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -10 183 (-6 757) · Earnings per share -0,21 (-0,18) · Cash and cash equivalents as of 31 March KSEK 51 831 (30 049) · Equity ratio as of 31 March 95,5 (90,3) % Significant events during the first quarter of 2020 · Cyxone announced in January that the company has ordered more Rabeximod substance earlier than planned. As a result, the first patient in the clinical Phase IIb trial is expected to be dosed in the first quarter of 2021.

There are no items matching the current filter
There are no more items matching the current filter
Back to top